Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback